Epigenetic therapy with decitabine for myelodysplasia and leukemia

Future Oncology

Volumn 1, Issue 5, 2005, Pages 585-591

  Wijermans, P ^a   Lubbert M ^b  

^a LEYENBURG HOSPITAL   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

5 aza 2 deoxycytidine; acute myeloid leukaemia; chronic myeloid; decitabine; epigenetic therapy; leukaemia; myelodysplastic syndrome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DRUG DERIVATIVE;

ANIMAL; CLINICAL TRIAL; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HUMAN; LEUKEMIA; METABOLISM; MYELODYSPLASTIC SYNDROME; REVIEW;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA; MYELODYSPLASTIC SYNDROMES;

EID: 33744925779     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.5.585     Document Type: Article

References (50)

1. Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in neoplasia pathophysiology and therapeutic implications. Ann. Intern. Med. 134, 573-586 (2001
2. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054 (2003
3. Bhalla KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 23, 3971-3993 (2005
4. Pliml J, Sorm F: Synthesis of 2′-deoxy-Dribofuranosyl- 5-azacytidine. Coll. Czech. Chem. Commun. 29, 2576-2577 (1964
5. Bouchard J, Momparler RL: Incorporation of 5-aza-2′-deoxycytidine into DNA: interaction with mammalian DNA polymerase and DNA methylase. Mol. Pharmacol. 24, 109-114 (1983
6. Creusot F, Acs G, Christman JK: Inhibition of DNA methyltransferase and induction of erythroleukemia cell differentiation by 5- azacytidine and 5-aza-2-deoxycytidine. J. Biol. Chem. 21, 117-121 (1982
7. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 20, 85-93 (1980
8. Baylin SB, Herman JG, Graff R, Vertino PM, Issa JP: Alteration in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141-196 (1998
9. Fischle W, Wang Y, Allis CD: Histone and chromatin crosstalk. Curr. Opin. Cell Biol. 15, 172-183 (2003
10. Attadia V: Effects of 5-aza-2-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukaemia cell line U-937. Leukemia 7(Suppl. 1), 9-16 (1993
11. Groeningen Van CJ, Leyva A, OBrien AMP, Gall HE, Pinedo HM: Phase I and pharmacokinetic studies of 5-aza- 2deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 46, 4831-4836 (1986
12. Chabot GG, Bouchard J, Montparler RL: Kinetics of deamination of 5-aza-2′- deoxycytidine and cytosine arabinoside by human liver cytidine and its inhibition by 3- deazauridine, thymidine or uracilarabinoside. Biochem. Pharmacol. 32, 1327-1328 (1983
13. Feinburg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92 (1983
14. Issa JP, Baylin SB, Hermans JG: DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 11(Suppl. 1), 7-11 (1997
15. Pinto A, Zagonel V, Gattei V: 5-Aza-2′- deoxycytidine as a differentiation inducer in human hemopoietic malignancies: preliminary observations on the in vivo modulation of leukaemia cell phenotype and correlation with clinical response. In:5-aza- 2-deoxycytidine: Preclinical and Clinical Studies. Momparler RL, de Vos D, Haarlem, PCH (Eds). The Netherlands, 143-164 (1990
16. Pinto A, Zagonel V, Attadia V et al.: 5-aza-2′- deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant. 4(Suppl. 3) 28-32 (1989
17. Wijermans PW, Krulder JWM, Huijgens PC, Neve P: Continuous infusion of low dose 5- aza-2′-deoxycytidine in elderly patient with high risk myelodysplastic syndrome. Leukemia 11, 1-5 (1997
18. Wijermans PW, Lübbert M, Verhoef G et al.: Low dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J. Clin. Oncol. 18, 956-962 (2000
19. Daskalakis M, Nguyen TT, Nguyen C et al.: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′- deoxycytidine (decitabine) treatment. Blood 100(8), 2957-2964 (2002
20. Issa JP, Garcia-Manero G, Giles FJ et al.: Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5- aza-2-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103, 1635-1640 (2004
21. Koshy M, Dorn L, Bressler L et al.: 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96, 2379-2384 (2000
22. DeSimone J, Koshy M, Dorn L et al.: Maintenance of elevated fetal hemoglobin levels by decitabine during dose nterval treatment of sickle cell anemia. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99, 3905-3908 (2002
23. Herman JG, Latif F, Weng Y et al.: Silencing of the VHL tumor suppressor gene by DNA hypomethylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700-9704 (1994
24. Merlo A, Herman JG, Mao L et al.: 5CpG island methylation is associated with tenscriptional silencing of the tumor suppressor p16/CNKN2/MTS1 in human cancers. Nature Med. 1, 696-702 (1995
25. Graff JR, Hermans JG, Lapidus RG et al.: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55, 5195-5199 (1995
26. Richel DJ, Colly LP, Lurvink E, Willemze R: Comparison of the antileukaemic activity of 5 aza-2′-deoxycytidine and arabinofuranosyl- cytosine in rats with myelocytic leukaemia. Br. J. Cancer 58(6), 730-733 (1988
27. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I: Induction of gene expression by 5-aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylationdependent and -independent mechanisms. Leukemia 19(1), 103-111 (2005
28. Zagonel V, Lo Re G, Marotta G et al.: 5-aza- 2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7(Suppl. 1), 30-35 (1993
29. Willemze R, Suciu S, Archimbaud E et al.: A randomized Phase II study on the effects of 5- aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC leukemia Co-operative Group Phase II study (06893). Leukemia 11 (Suppl. 1), 24-27 (1997
30. WijermansP, Lübbert M, Verhoef G, Klimek V, Bosly A: An epigenetic approach to the treatment of advanced MDS: the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. (Submitted)
31. Cheson BD, Bennett JM, Kantarjian H et al.: World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96, 3671-3674 (2000
32. van den Bosch J, Lübbert M, Verhoef G, Wijermans PW: The effects of 5-aza-2′- deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk. Res. 28, 785-790 (2004
33. Lübbert M, Wijermans P, Kunzmann R et al.: Cytogenetic responses in high-risk myelodysplastic syndrome following lowdose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. 114, 349-357 (2001
34. Lübbert M, Daskalakis M, Kunzmann R, Engelhardt M, Guo Y, Wijermans P: Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2′-deoxycytidine (decitabine). Leuk. Res. 28, 1267-1271 (2004
35. Silverman LR, Demakos EP, Peterson BL et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20, 2429-2440 (2002
36. Saba H, Rosenfeld C, Issa JP et al.: First report of the Phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS). Blood 104, 23A (2004
37. Saba HI, Issa JPJ, Bennett J et al.: Decitabine, a hypomethylating agent is more effective than supportive care in patients with myelodysplastic syndrome (MDS). J. Clin. Oncol. 23(Suppl. 16), S570 (Abstract 6543) (2005
38. Lübbert M, Wijermans PW, Rüter BH: Retreatment with low dose 5-aza-2′- deoxycytidine; results in second remissions of previously responsive MDS patients. Blood 104(Suppl.), 405a (2004
39. Pinto A, Attadia V, Di Fiore PP et al.: 2-deoxy-5-azacytidine induces functional and morphological differentiation of a human erythroleukemic cell line (K562). In:Leukemia Rev. Int. 1, Rich MA (Ed), New York, NY, USA, Marcel Dekker, 207-208 (1983
40. Pinto A, Attadia V, Fusco A et al.: 5-Aza-2′- deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64, 922-929, (1984
41. Momparler RL, Bouchard J, Onetto N et al.: 5-aza-2′-deoxycytidine therapy in patients with acute leukaemia inhibits DNA methylation. Leukemia Res. 8, 181-185 (1984
42. Rivard GE, Momparler RL, Demers J et al.: Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leukemia. Res. 5, 453-462 (1981
43. Petti MC, Mandelli F, Zagonel V et al.: Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia. 7(Suppl. 1), 36-41 (1993
44. Ruter B, Wijermans PW, Lubbert M: DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia. Int. J. Hematol. 80(2), 128-135 (2004
45. Garcia-Manero G, Kantarjian H, Sanchez B et al.: Results of a Phase I/II of the combination of 5-aza-2′-deoxycytidine (DAC) and Valproic acid (VPA) in patients with leukaemia. Blood 104, 78a (2004
46. Zion M, Ben-Yehuda D, Avraham A et al.: Progressive de novo DNA methylation at the BCR-ABL locus in the course of chronic myelogenous leukemia. Proc. Natl Acad. Sci. USA 91, 10722-10726 (1994
47. Nguyen TT, Mohrbacher AF, Tsai YC et al.: Quantitative measure of C-ABL and p15 methylation in chronic myelogenous leukemia: biological implications. Blood 95, 2990-2992 (2000
48. Sacchi S, Kantarjian HM, OBrien S et al.: Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86, 2632-2641 (1999
49. Kantarjian HM, OBrien S, Cortes J et al.: Results of decitabine (5-aza-2′- deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98, 522-528 (2003
50. Lübbert M, Wijermans P, Verhoef G: Karyotypic stability or chromosomal evolution during treatment with a DNA demethylating agent? A serial study of patients with the myelodysplastic syndrome. Blood 102 (Suppl.), 427 (2003